R Squared Ltd Buys Shares of 8,410 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

R Squared Ltd bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 8,410 shares of the biopharmaceutical company’s stock, valued at approximately $79,000.

Other institutional investors have also added to or reduced their stakes in the company. Hazlett Burt & Watson Inc. boosted its holdings in shares of Amicus Therapeutics by 156.9% in the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,569 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Amicus Therapeutics by 21.3% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 1,884 shares in the last quarter. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at about $26,000. AlphaCentric Advisors LLC boosted its holdings in shares of Amicus Therapeutics by 1.2% in the 3rd quarter. AlphaCentric Advisors LLC now owns 205,000 shares of the biopharmaceutical company’s stock valued at $2,189,000 after buying an additional 2,500 shares in the last quarter. Finally, Diversified Trust Co boosted its holdings in shares of Amicus Therapeutics by 3.8% in the 3rd quarter. Diversified Trust Co now owns 74,501 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 2,698 shares in the last quarter.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $9.58 on Friday. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42. The stock has a fifty day moving average price of $9.64 and a 200 day moving average price of $10.48. Amicus Therapeutics, Inc. has a 1-year low of $8.78 and a 1-year high of $14.03. The company has a market cap of $2.86 billion, a PE ratio of -28.18, a P/E/G ratio of 1.54 and a beta of 0.62.

Insiders Place Their Bets

In related news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total transaction of $75,150.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,884,273.08. This trade represents a 0.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.20% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the stock. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Morgan Stanley reiterated an “equal weight” rating and issued a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. Guggenheim lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Finally, JPMorgan Chase & Co. raised their price target on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Amicus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.